Sarcoma: open trials in China

106 open trials have a site in China. Registry data; only the trial team decides who can take part.

NCT04390737
Evaluate the Safety and Clinical Activity of HH2853
Trial Treatment · Phase 1/2 · Haihe Biopharma Co., Ltd.
Beijing Jishuitan Hospital, Beijing · Beijing Cancer Hospital, Beijing · Hunan Cancer Hospital, Changsha · West China Hospital of Sichuan University, Chengdu · Sun Yat-sen University Cancer Hospital, Guangzhou · Zhejiang Cancer Hospital, Hangzhou · The First Affiliated Hospital of Anhui Medical University, Hefei · Linyi Tumor Hospital, Linyi · Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing · Affiliated Tumor Hospital of Guangxi Medical University, Nanning · Shanghai Sixth People's Hospital, Shanghai · Zhongshan Hospital,Fudan University, Shanghai · Liaoning Cancer Hospital & Institute, Shenyang · Shengjing Hospital Of China Medical University, Shenyang · Shanxi Cancer hospital, Taiyuan · Tianjin Cancer Hospital, Tianjin · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan · Henan Cancer Hospital, Zhengzhou
Registry updated 2026-01-30
NCT07359053
MAGNATE-S: Paclitaxel Polymer Micelles Combo in Advanced Sarcoma
Trial Treatment · Phase 2 · Shanghai 6th People's Hospital
Shanghai Sixth Peolple'S Hospital, Shanghai
Registry updated 2026-01-22
NCT07355855
A Clinical Study on the Efficacy and Safety of All-trans Retinoic Acid Combined With VAC Regimen in the Treatment of Intermediate-to-high-risk Rhabdomyosarcoma
Trial Treatment · Phase 2 · Fudan University
Fudan University Cancer hospital, Shanghai
Registry updated 2026-01-21
NCT07342322
A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Spatially Fractionated Radiotherapy Combined With the PraG Strategy for the Treatment of Soft Tissue Sarcoma
Trial Treatment · Phase 2 · First Affiliated Hospital of Guangxi Medical University
The First Affiliated Hospital of Guangxi Medical University, Nanning
Registry updated 2026-01-15
NCT07342738
TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors
Trial Treatment · Early phase 1 · Sun Yat-sen University
Sun Yat-sen University Cancer Center, Guangzhou
Registry updated 2026-01-15
NCT06849986
IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)
Trial Treatment · Phase 2 · Fudan University
Fudan University Shanghai Cancer Center, Shanghai
Registry updated 2026-01-08
NCT05224934
Preoperative Ultra-hypofractionated Radiotherapy Followed by Surgery for Retroperitoneal Sarcoma (FUSION-01)
Trial Treatment · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Radiotherapy Department of Cancer Hospital, Chinese Academy of Medical Sciences, Beijing
Registry updated 2025-12-11
NCT06939855
QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma
Trial Treatment · Phase 2 · Sun Yat-sen University
Sun Yat-sen University Cancer Center, Guangzhou
Registry updated 2025-11-19
NCT06667544
A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation
Trial Treatment · Phase 1/2 · Ranok Therapeutics (Hangzhou) Co., Ltd.
Zhejiang Cancer Hospital, Hangzhou · Guangxi Medical University Cancer Hospital, Nanning · Shanghai Chest Hospital, Shanghai · Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan · Henan Cancer Hospital, Zhengzhou
Registry updated 2025-10-30
NCT07153887
Vebreltinib for Advanced or Metastatic CCS
Trial Treatment · Phase 2 · Second Affiliated Hospital, Zhejiang University, School of Medicine
The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou
Registry updated 2025-09-30
NCT07156643
A Prospective, Single-arm, Multicenter Exploratory Clinical Study of Anlotinib Combined With Bempegaldesleukin and Conventional Chemoradiotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma.
Trial Treatment · Phase 2 · The First Affiliated Hospital with Nanjing Medical University
Jiangsu Province Hospital, Nanjing
Registry updated 2025-09-05
NCT06942143
An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors
Trial Treatment · Phase 1 · Guangzhou FineImmune Biotechnology Co., LTD.
Sun Yat-sen University Cancer Center, Guangzhou
Registry updated 2025-09-03
NCT07142863
Envafolimab Combined With Neoadjuvant Chemotherapy Treat Stage IIb Resectable Osteosarcoma Patients
Trial Treatment · Phase 2 · Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai First People's Hospital, 100 Haining Road, Hongkou District, Shanghai
Registry updated 2025-08-27
NCT06683846
Ivonescimab in the Treatment of Multiple Advanced Tumors
Trial Treatment · Phase 2 · Fudan University
Fudan University Cancer hospital, Shanghai
Registry updated 2025-08-24
NCT06508307
A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
Trial Treatment · Phase 1 · GONGCHU Biotechnology Co., Ltd
Henan Cancer Hospital, Zhengzhou
Registry updated 2025-08-21
NCT06277154
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
Trial Treatment · Phase 2 · HRYZ Biotech Co.
Sun Yat-sen University Cancer Center, Guangzhou
Registry updated 2025-07-24
NCT06367075
A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue Sarcoma
Trial Treatment · Phase 2 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Registry updated 2025-07-18
NCT07067255
Sequential CD146 and GPC3 CAR-T Cell Therapy in Advanced Ovarian Cancer
Trial Treatment · Phase 1/2 · Essen Biotech
District One Hospital, Beijing
Registry updated 2025-07-16
NCT07066982
Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas
Trial Treatment · Phase 1/2 · Essen Biotech
District One Hospital, Beijing
Registry updated 2025-07-15
NCT07028086
VAM in Secondary AML, AML With Extramedullary Involvement, and Myeloid Sarcoma
Trial Treatment · Phase 2 · Ruijin Hospital
Ruijin Hospital Shanghai Jiaotong University School of Medicine, Shanghai
Registry updated 2025-07-09
NCT06827717
Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma
Trial Treatment · Phase 2 · Sun Yat-sen University
Sun Yat-sen University Cancer Center, Guangzhou
Registry updated 2025-05-31
NCT04072042
BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced or Metastatic Sarcoma
Trial Treatment · Phase 2 · Ruijin Hospital
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai
Registry updated 2025-05-14
NCT05894018
Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma
Trial Treatment · Phase 2 · Fujun Zhang
Sun Yat-sen University Cancer Center, Guangzhou
Registry updated 2025-05-13
NCT06848582
Umbilical Cord Blood NK Cell Therapy for High-Risk Pediatric Soft Tissue Sarcoma: Efficacy and Safety Study
Trial Treatment · Sun Yat-sen University
Dongguan Taixin Hospital, Dongguan · Sun Yat-sen University Cancer Center, Guangzhou
Registry updated 2025-02-27
NCT04785196
APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors
Trial Treatment · Phase 1/2 · Ascentage Pharma Group Inc.
Sun Yat-sen University Cancer Center, Guangzhou · Cancer Hospital of The University of Chinese Academy of Sciences, Hangzhou · Shanghai East Hospital (East Hospital Affiliated to Tongji University), Shanghai
Registry updated 2025-02-26

All Sarcoma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error